Virtus ETF Advisers’s Praxis Precision Medicines PRAX Stock Holding History

Virtus ETF Advisers’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,001	Closed	-$77K	–	697
2024 Q4	$77K	Sell	1,001 -1,296	-56%	-$93.8K	0.03%	344
2024 Q3	$132K	Buy	2,297 +37	+2%	+$2K	0.06%	341
2024 Q2	$93.5K	Buy	+2,260	New	+$107K	0.05%	342
2022 Q2	–	Sell	-568	Closed	-$87K	–	466
2022 Q1	$87K	Sell	568 -34	-6%	-$6.98K	0.04%	323
2021 Q4	$178K	Sell	602 -82	-12%	-$24.1K	0.07%	255
2021 Q3	$190K	Sell	684 -36	-5%	-$9.77K	0.08%	282
2021 Q2	$197K	Buy	+720	New	+$258K	0.08%	354

Other funds holding PRAX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Virtus ETF Advisers's PRAX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Praxis Precision Medicines (PRAX) in Q1 2025, closing a stake of 1,001 shares — an estimated $77K sold.

Virtus ETF Advisers first reported a position in PRAX in Q2 2021 and held it in 7 quarters. The position peaked at $197K in Q2 2021. 150 funds tracked by Wall St. Rank hold PRAX as of Q1 2025.

Virtus ETF Advisers reported no remaining Praxis Precision Medicines position as of Q1 2025 after selling out during the quarter.
Virtus ETF Advisers sold 1,001 Praxis Precision Medicines shares in Q1 2025, an estimated $77K.
Virtus ETF Advisers first reported a position in Praxis Precision Medicines in Q2 2021 and held it in 7 quarters.
Virtus ETF Advisers's Praxis Precision Medicines position peaked at $197K in Q2 2021.
150 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.